RNXT RenovoRx

Genentech Tecentriq FDA approved for Stage III dMMR colon cancer

FDA approved atezolizumab (Tecentriq) in combination with fluoropyrimidine and oxaliplatin for adjuvant treatment of adult and pediatric patients >=2 years with Stage III dMMR colon cancer. This is a new adjuvant indication for the PD-L1 inhibitor in this setting.

RenovoCath · NCT03257033 registry update

status: RECRUITING → ACTIVE_NOT_RECRUITING; countries: {'total_sites': 42, 'us_sites': 36} → {'total_sites': 31, 'us_sites': 26}

RNXT: TIGeR-PaC Phase 3 fully enrolled; topline data H2 2027

Phase III TIGeR-PaC trial evaluating intra-arterial gemcitabine via RenovoCath reached full enrollment. Trial completion expected in H1 2027 after 86 events; topline data readout now guided for H2 2027. 15 trial sites are positioned to transition to commercial RenovoCath use.

RenovoRx to Highlight TAMP Platform at JonesTrading KOL Webinar on Pancreatic Cancer

The company announced participation in a JonesTrading virtual KOL webinar on August 13, 2026 at 1:30 p.m. ET. The webinar will cover the TAMP platform, RenovoCath device, and the ongoing Phase III TIGeR-PaC trial. RenovoRx also noted full TIGeR-PaC enrollment expected soon and final data readout in mid to late 2027.

RenovoRx: FDA grants ODD to oxaliplatin for pancreatic cancer

FDA granted Orphan Drug Designation to oxaliplatin for pancreatic cancer, providing seven years of market exclusivity upon approval, a 25% tax credit on qualified clinical expenses, and a waiver of FDA application fees. This is RenovoRx’s third ODD overall and second in pancreatic cancer, expanding the pipeline beyond its existing IAG designation.

RenovoRx TIGeR-PaC Phase 3 enrollment on track for mid-2026

The company updated that the Phase 3 TIGeR-PaC trial has randomized 104 patients with 72 events observed and remains on track for full enrollment of 114 patients by mid-2026. Final data are now guided for 2027, and 17 trial centers are expected to transition to commercial RenovoCath customers in H2 2026.